Antimicrobial resistance surveillance in ireland
This presentation is the property of its rightful owner.
Sponsored Links
1 / 37

Antimicrobial resistance surveillance in Ireland PowerPoint PPT Presentation


  • 59 Views
  • Uploaded on
  • Presentation posted in: General

Antimicrobial resistance surveillance in Ireland. Results of invasive enterococcal bacteraemia surveillance, 2009 **** Data as of 01/12/2010 ****. Ireland is a member of the European Antimicrobial Resistance Surveillance Network (EARS-Net).

Download Presentation

Antimicrobial resistance surveillance in Ireland

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Antimicrobial resistance surveillance in ireland

Antimicrobial resistance surveillance in Ireland

Results of invasive enterococcal bacteraemia surveillance, 2009

**** Data as of 01/12/2010 ****

Ireland is a member of the European Antimicrobial Resistance Surveillance Network (EARS-Net)


Ears net enterococci objective and case definition

EARS-Net Enterococci:Objective and case definition

Objective:

  • To determine the proportions of enterococci, E. faecalis or E. faecium, isolates from blood that are resistant to 3 key antibiotic classes:

    • Ampicillin

    • High-level gentamicin

    • Vancomycin

      Case definition:

  • EARS-Net collects data on the first invasive isolate (from blood only) of E. faecium per patient per quarter


Caveats in interpreting ears net data

Caveats in interpreting EARS-Net data

  • Care must be exercised when interpreting the raw figures, i.e. increases in numbers of isolates, as the numbers of laboratories reporting to EARS-Net has increased over the years

  • EARS-Net data does not distinguish clinically significant isolates from contaminants

  • If a resistant isolate is identified subsequent to a susceptible one within the same quarter, then that isolate is not counted (and similarly if susceptible isolates is identified subsequent to resistant one)


Antimicrobial resistance surveillance in ireland

For further information on antimicrobial resistance and EARS-Net in Ireland, including quarterly and annual reports, plus reference/ resource material on the individual pathogens under surveillance, see:

http://www.hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/


Antibiotic codes and abbreviations

Antibiotic codes and abbreviations:

AMP, Ampicillin HLG, High-Level Gentamicin

LNZ, Linezolid QDA, Quinupristin-Dalfopristin

TEC, Teicoplanin VAN, Vancomycin

AMR, Antimicrobial Resistance

MDR, Multi-Drug Resistance

EFA, Enterococcus faecalis

EFM, Enterococcus faecium

VREfm, Vancomycin-Resistant E. faecium

VSEfm, Vancomycin-Susceptible E. faecium

MDR, Multi-Drug Resistance


Enterococcus faecalis

Enterococcus faecalis


Numbers and resistance proportions of e faecalis from bacteraemia 2002 2009

Numbers and resistance proportions of E. faecalis from bacteraemia, 2002-2009

* Not all isolates tested


E faecalis bacteraemia resistance trends 2002 2009

E. faecalis bacteraemia resistance trends, 2002-2009

Number of laboratories participating by year-end and quarter are indicated above the bars


Numbers and proportions of e faecalis bacteraemia by hospital type 2009

Numbers and proportions of E. faecalis bacteraemia by hospital type, 2009


Susceptibility data for e faecalis bacteraemia isolates 2009 n 389

Susceptibility data for E. faecalis bacteraemia isolates, 2009 (n=389)


Resistance profiles of e faecalis isolates in 2009

Resistance profiles of E. faecalis isolates in 2009


Age and sex distribution of patients with invasive e faecalis infection in 2009

Age and sex distribution of patients with invasive E. faecalis infection in 2009


Age and sex specific incidence rates of e faecalis bacteraemia in 2009

Age and sex-specific incidence rates of E. faecalis bacteraemia in 2009

ASIR, Age-Specific Incidence Rate (per 100,000 population)


Mean median mode and range of ages of patients with e faecalis bacteraemia in 2009

Mean, median, mode and range of ages of patients with E. faecalis bacteraemia in 2009


Sex distribution of patients with e faecalis bacteraemia in 2009

Sex distribution of patients with E. faecalis bacteraemia in 2009

In patients with laboratory-confirmed invasive E. faecalis infection in 2009, males were approximately 1.6-times more likely to get an infection than females (highly significant, P<0.0001).


E faecalis distribution of high level gentamicin resistance in earss ears net countries 2009

E. faecalis - distribution of high-level gentamicin resistance in EARSS/EARS-Net countries, 2009

Map downloaded from:

http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx on 21/12/2010


E faecalis distribution of high level gentamicin resistance in earss countries 2008

E. faecalis - distribution of high-level gentamicin resistance in EARSS countries, 2008

Map downloaded from http://www.rivm.nl/earss/database/ on 24/08/2009


E faecalis distribution of vancomycin resistance in earss ears net countries 2009

E. faecalis - distribution of vancomycin resistance in EARSS/EARS-Net countries, 2009

Map downloaded from:

http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx on 21/12/2010


E faecalis distribution of vancomycin resistance in earss countries 2008

E. faecalis - distribution of vancomycin resistance in EARSS countries, 2008

Map downloaded from http://www.rivm.nl/earss/database/ on 24/08/2009


Enterococcus faecium

Enterococcus faecium


Numbers and resistance proportions of e faecium from bacteraemia 2002 2009

Numbers and resistance proportions of E. faecium from bacteraemia, 2002-2009

* Not all isolates tested


E faecium bacteraemia resistance trends 2002 2009

E. faecium bacteraemia resistance trends, 2002-2009

Number of laboratories participating by year-end and quarter are indicated above the bars


Invasive mdr e faecium trends 2002 2009

Invasive MDR E. faecium trends, 2002-2009

Number of laboratories participating by year-end and quarter are indicated above the bars


Numbers and proportions of vrefm bacteraemia by hospital type 2009

Numbers and proportions of VREfm bacteraemia by hospital type, 2009


Numbers and proportions of mdr e faecium bacteraemia by hospital type 2009

Numbers and proportions of MDR E. faecium bacteraemia by hospital type, 2009


Susceptibility data for e faecium bacteraemia isolates 2009 n 397

Susceptibility data for E. faecium bacteraemia isolates, 2009 (n=397)


Resistance profiles of e faecium isolates in 2009

Resistance profiles of E. faecium isolates in 2009


Trends in numbers of main resistance profiles of e faecium isolates 2002 2009

Trends in NUMBERS of main resistance profiles of E. faecium isolates, 2002-2009

Number of laboratories participating by year-end and quarter are indicated above the bars


Trends in proportions of main resistance profiles of e faecium isolates 2002 2009

Trends in PROPORTIONS of main resistance profiles of E. faecium isolates, 2002-2009


Age and sex distribution of patients with invasive e faecium infection in 2009

Age and sex distribution of patients with invasive E. faecium infection in 2009


Age and sex specific incidence rates of e faecium bacteraemia in 2009

Age and sex-specific incidence rates of E. faecium bacteraemia in 2009

ASIR, Age-Specific Incidence Rate (per 100,000 population)


Mean median mode and range of ages of patients with e faecium bacteraemia in 2009

Mean, median, mode and range of ages of patients with E. faecium bacteraemia in 2009


Sex distribution of patients with e faecium bacteraemia in 2009

Sex distribution of patients with E. faecium bacteraemia in 2009

In patients with laboratory-confirmed invasive E. faecium infection in 2009, males were approximately 1.3-times more likely to get an infection than females (significant, P=0.005).


E faecium distribution of high level gentamicin resistance in earss ears net countries 2009

E. faecium - distribution of high-level gentamicin resistance in EARSS/EARS-Net countries, 2009

Map downloaded from:

http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx on 21/12/2010


E faecium distribution of high level gentamicin resistance in earss countries 2008

E. faecium - distribution of high-level gentamicin resistance in EARSS countries, 2008

Map downloaded from http://www.rivm.nl/earss/database/ on 24/08/2009


E faecium distribution of vancomycin resistance in earss ears net countries 2009

E. faecium - distribution of vancomycin resistance in EARSS/EARS-Net countries, 2009

Map downloaded from:

http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx on 21/12/2010


E faecium distribution of vancomycin resistance in earss countries 2008

E. faecium - distribution of vancomycin resistance in EARSS countries, 2008

Map downloaded from http://www.rivm.nl/earss/database/ on 24/08/2009


  • Login